Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free APLS Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Apellis Pharmaceuticals (APLS) Earnings Date, Estimates & Call Transcripts

Apellis Pharmaceuticals logo
Compare

Apellis Pharmaceuticals Earnings Summary

Apellis Pharmaceuticals announced Q1 2026 earnings on May 7, 2026, reporting an EPS of $0.15, which beat analysts' consensus estimates of -$0.29 by $0.44. Quarterly revenue was reported to be $268.30 million, above the consensus estimate of $208.91 million. With a trailing EPS of $1.02 and a P/E Ratio of 40.23, Apellis Pharmaceuticals' earnings are expected to grow next year, from ($1.14) to ($0.44) per share.

Latest Q1
Earnings Date
May. 7Estimated
Consensus EPS
(May. 7)
-$0.29
Actual EPS
(May. 7)
$0.15 Beat By $0.44
Actual Revenue
(May. 7)
$268.30M

Q1 2026 Earnings Resources

Powered by Quartr
Get Apellis Pharmaceuticals Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Apellis Pharmaceuticals and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

APLS Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

APLS Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Apellis Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20264-$0.69-$0.38-$0.55
Q2 20264-$0.51-$0.17-$0.40
Q3 20264-$0.60-$0.06-$0.36
Q4 20264-$0.47$0.08-$0.28
FY 2026 16 -$2.27 -$0.53 -$1.59
Q1 20271-$0.33-$0.33-$0.33
Q2 20271-$0.20-$0.20-$0.20
Q3 20271-$0.26-$0.26-$0.26

Apellis Pharmaceuticals Earnings History by Quarter

Export
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026-$0.2888$0.15+$0.4388$0.15$208.91M$268.30M
2/24/2026Q4 2025-$0.39$0.47+$0.86-$0.45$199.28M$199.91M
10/30/2025Q3 2025$1.03$1.67+$0.64$1.67$364.58M$458.58M
7/31/2025Q2 2025-$0.44-$0.33+$0.11-$0.33$187.91M$171.39M
5/7/2025Q1 2025-$0.36-$0.74 -$0.38-$0.74$197.61M$149.90M
2/28/2025Q4 2024-$0.37-$0.29+$0.08-$0.29$197.92M$212.50M
11/5/2024Q3 2024-$0.32-$0.46 -$0.14-$0.46$200.00M$196.83M

Apellis Pharmaceuticals Earnings - Frequently Asked Questions

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earning data on Thursday, May 7, 2026. Learn more on APLS's earnings history.

In the previous quarter, Apellis Pharmaceuticals (NASDAQ:APLS) reported $0.15 earnings per share (EPS) to beat the analysts' consensus estimate of ($0.29) by $0.44. Learn more on analysts' earnings estimate vs. APLS's actual earnings.

Apellis Pharmaceuticals' earnings report can be found in their filing with the SEC.
View SEC filing

Apellis Pharmaceuticals (NASDAQ:APLS) has a recorded annual revenue of $1.11 billion.

Apellis Pharmaceuticals (NASDAQ:APLS) has a recorded net income of $22.39 million. APLS has generated $1.02 earnings per share over the last four quarters.

Apellis Pharmaceuticals (NASDAQ:APLS) has a trailing price-to-earnings ratio of 40.23.

Apellis Pharmaceuticals' earnings are expected to grow from ($1.14) per share to ($0.44) per share in the next year.

Related Companies
Earnings Tools

Earnings data for NASDAQ:APLS is sourced from Fiscal.ai, with the most recent quarter reported on 5/7/2026. New results are added as companies report their earnings.
From Our Partners
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Buy These Stocks Before August 31st
Keith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...
TradeSmith | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...
Porter & Company | Sponsoredtc pixel
125X bigger gains than Nvidia?
Tech investor Jeff Brown says a new supercycle may be forming in a sector most investors are ignoring, and he ...
Brownstone Research | Sponsoredtc pixel